LANTHEUS HOLDINGS, INC. (LNTH) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
LANTHEUS HOLDINGS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $75,029,000.00Depreciation, amortization and accretion → Operating adjustments reconciliation: $22,582,000.00Stock-based compensation → Operating adjustments reconciliation: $20,007,000.00Unrealized (gain) loss on investment in equity securities → Operating adjustments reconciliation: $9,536,000.00Other current and noncurrent assets → Operating adjustments reconciliation: $5,088,000.00Inventory → Operating adjustments reconciliation: $3,301,000.00Accounts receivable → Operating adjustments reconciliation: $3,276,000.00Accounts payable → Operating adjustments reconciliation: $1,390,000.00Amortization of debt-related costs → Operating adjustments reconciliation: $1,115,000.00Long-term income tax payable and other long-term liabilities → Operating adjustments reconciliation: $603,000.00Inventory adjustments → Operating adjustments reconciliation: $454,000.00Operating adjustments reconciliation → Net cash from operating activities: $17,174,000.00Operating adjustments reconciliation → Change in fair value of contingent liabilities: $31,397,000.00Operating adjustments reconciliation → Deferred taxes: $13,071,000.00Operating adjustments reconciliation → Gain on conversion of Installment Note: $2,525,000.00Operating adjustments reconciliation → Accrued expenses and other current and noncurrent liabilities: $1,989,000.00Operating adjustments reconciliation → Other: $997,000.00Operating adjustments reconciliation → Gain on sale of business, net of transaction costs: $199,000.00Proceeds from stock option exercises → financing reconciliation: $6,856,000.00financing reconciliation → Net cash from financing activities: $4,505,000.00financing reconciliation → Payments for minimum statutory tax withholding related to net share settlement of equity awards: $2,102,000.00financing reconciliation → Payments of long-term debt and other borrowings: $248,000.00financing reconciliation → Proceeds from employee stock purchase plan: $1,000.00Net cash used in investing activities → investing reconciliation: $2,023,000.00Acquisition, net of cash acquired - Lantheus Biosciences Ltd → investing reconciliation: $312,000.00investing reconciliation → Capital expenditures: $2,335,000.00Exchange-rate effect → Cash sources and uses: $36,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $500,294,000.00Net cash from operating activities → Cash sources and uses: $92,203,000.00Net cash from financing activities → Cash sources and uses: $4,505,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $595,015,000.00Cash sources and uses → Net cash used in investing activities: $2,023,000.00Accounts payable: $1,390,000.00Accounts payable+$1.39 MUnrealized (gain) loss on investment in equity securities: $9,536,000.00Unrealized equity gain & loss+$9.54 MAmortization of debt-related costs: $1,115,000.00Debt issuance cost amortization+$1.12 MGain on conversion of Installment Note: -$2,525,000.00Note conversion gain−$2.53 MGain on sale of business, net of transaction costs: -$199,000.00Business sale gain & loss−$199.00 KChange in fair value of contingent liabilities: -$31,397,000.00Contingent liability fair value−$31.40 MLong-term income tax payable and other long-term liabilities: $603,000.00Other noncurrent liabilities+$603.00 KNet income: $75,029,000.00Net income+$75.03 MDeferred taxes: -$13,071,000.00Deferred taxes−$13.07 MDepreciation, amortization and accretion: $22,582,000.00D&A and accretion+$22.58 MAdjustment to the fair value of asset retirement obligation: $0.00Inventory: $3,301,000.00Inventories+$3.30 MOther current and noncurrent assets: $5,088,000.00Other operating assets+$5.09 MAccrued expenses and other current and noncurrent liabilities: -$1,989,000.00Accrued liabilities−$1.99 MCharges incurred pursuant to acquired in-process research and development: $0.00Other: -$997,000.00Other non-cash items−$997.00 KStock-based compensation: $20,007,000.00Stock-based compensation+$20.01 MInventory adjustments: $454,000.00Inventory write-downs+$454.00 KAccounts receivable: $3,276,000.00Accounts receivable+$3.28 MNet cash from operating activities: $92,203,000.00Operating cash+$92.20 MOperating adjustments reconciliation: $67,352,000.00Proceeds from stock option exercises: $6,856,000.00Stock option exercises+$6.86 MRepurchase of common stock: $0.00Proceeds from employee stock purchase plan: -$1,000.00Stock plan proceeds−$1.00 KPayments of long-term debt and other borrowings: -$248,000.00Long-term debt repaid−$248.00 KPayments for minimum statutory tax withholding related to net share settlement of equity awards: -$2,102,000.00Stock-award tax withholding−$2.10 MNet cash from financing activities: $4,505,000.00Financing cash+$4.51 Mfinancing reconciliation: $6,856,000.00Acquisition of in-process research and development: $0.00Acquisition, net of cash acquired - Evergreen Theragnostics: $0.00Acquisition, net of cash acquired - Lantheus Biosciences Ltd: $312,000.00Acquisitions: Lantheus+$312.00 KProceeds from sale of business, net of transaction costs: $0.00Capital expenditures: -$2,335,000.00Capital improvements−$2.34 MProceeds from sale of assets: $0.00Purchases of investment in equity securities: $0.00Net cash used in investing activities: -$2,023,000.00. Cash required to fund net payments.Investing cash−$2.02 Minvesting reconciliation: $2,335,000.00Cash sources and uses: $597,038,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $500,294,000.00Beginning cash$500.29 MEnding cash: Cash, cash equivalents, and restricted cash: $595,015,000.00Ending cash$595.02 MExchange-rate effect: $36,000.00FX effect+$36.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flowNot availableCash flow / Net income1.23×Operating cash flow ÷ net incomeNet cash change+$94.72 MEnding cash − beginning cash
Chart details

LANTHEUS HOLDINGS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
500,294,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
92,203,000 US dollars. Net cash provided.
Net income
75,029,000 US dollars
Accounts payable
1,390,000 US dollars
Unrealized (gain) loss on investment in equity securities
9,536,000 US dollars
Amortization of debt-related costs
1,115,000 US dollars
Gain on conversion of Installment Note
negative 2,525,000 US dollars
Gain on sale of business, net of transaction costs
negative 199,000 US dollars
Change in fair value of contingent liabilities
negative 31,397,000 US dollars
Long-term income tax payable and other long-term liabilities
603,000 US dollars
Deferred taxes
negative 13,071,000 US dollars
Depreciation, amortization and accretion
22,582,000 US dollars
Adjustment to the fair value of asset retirement obligation
0 US dollars
Inventory
3,301,000 US dollars
Other current and noncurrent assets
5,088,000 US dollars
Accrued expenses and other current and noncurrent liabilities
negative 1,989,000 US dollars
Charges incurred pursuant to acquired in-process research and development
0 US dollars
Other
negative 997,000 US dollars
Stock-based compensation
20,007,000 US dollars
Inventory adjustments
454,000 US dollars
Accounts receivable
3,276,000 US dollars
Investing activities
negative 2,023,000 US dollars. Net cash used.
Acquisition of in-process research and development
0 US dollars
Acquisition, net of cash acquired - Evergreen Theragnostics
0 US dollars
Acquisition, net of cash acquired - Lantheus Biosciences Ltd
312,000 US dollars
Proceeds from sale of business, net of transaction costs
0 US dollars
Capital expenditures
negative 2,335,000 US dollars
Proceeds from sale of assets
0 US dollars
Purchases of investment in equity securities
0 US dollars
Financing activities
4,505,000 US dollars. Net cash provided.
Proceeds from stock option exercises
6,856,000 US dollars
Repurchase of common stock
0 US dollars
Proceeds from employee stock purchase plan
negative 1,000 US dollars
Payments of long-term debt and other borrowings
negative 248,000 US dollars
Payments for minimum statutory tax withholding related to net share settlement of equity awards
negative 2,102,000 US dollars
Operating adjustment reconciliation
67,352,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
6,856,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
2,335,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
36,000 US dollars
Ending cash on Jun 30, 2026
595,015,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
597,038,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
94,721,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.23×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $17.17M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
LANTHEUS HOLDINGS, INC. (LNTH) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!